Comparison of hormonal receptor expression and HER2 status between circulating tumor cells and breast cancer metastases
Open Access
Abstract
Breast cancer (BC) is the most common neoplasm in women. Biopsy of metastatic lesions is recommended to confirm estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status as there are discrepancies in ...Keywords
This publication has 68 references indexed in Scilit:
- TGF-β inhibition enhances chemotherapy action against triple-negative breast cancerJournal of Clinical Investigation, 2013
- The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancerBreast Cancer Research and Treatment, 2012
- Circulating tumour cells in non-metastatic breast cancer: a prospective studyThe Lancet Oncology, 2012
- The microenvironment in breast cancer progression: biology and implications for treatmentBreast Cancer Research, 2011
- Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapyAnnals of Oncology, 2011
- A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomasBritish Journal of Cancer, 2011
- Transforming growth factor-β in breast cancer: too much, too lateBreast Cancer Research, 2009
- A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancerNature Medicine, 2009
- Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall SurvivalClinical Cancer Research, 2006
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004